Multimodal immunogenomic biomarker analysis of tumors from pediatric patients enrolled to a phase 1-2 study of single-agent atezolizumab

We report herein an exploratory biomarker analysis of refractory tumors collected from pediatric patients before atezolizumab therapy (iMATRIX-atezolizumab, NCT02541604). Elevated levels of CD8(+) T cells and PD-L1 were associated with progression-free survival and a diverse baseline infiltrating T-...

Descripción completa

Detalles Bibliográficos
Autores principales: Nabbi, Arash, Danesh, Arnavaz, Espin-Garcia, Osvaldo, Pedersen, Stephanie, Wellum, Johanna, Fu, Lingyan Helen, Paulson, Joseph N., Geoerger, Birgit, Marshall, Lynley V., Trippett, Tanya, Rossato, Gianluca, Pugh, Trevor J., Hutchinson, Katherine E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10132976/
https://www.ncbi.nlm.nih.gov/pubmed/37038005
http://dx.doi.org/10.1038/s43018-023-00534-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10132976/
https://www.ncbi.nlm.nih.gov/pubmed/37038005
http://dx.doi.org/10.1038/s43018-023-00534-x

Ejemplares similares